Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MW151 With Whole-brain Radiotherapy in Intracranial Metastases
NCT05417282Phase 1Completed
- Sponsor
- ImmunoChem Therapeutics
- Start
- Jul 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MW151 in cognitive dysfunction, sponsored by ImmunoChem Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 28 days. Started Jul 2022; status: completed.
02
Drugs
MW151
03
Conditions
cognitive dysfunction
Beyond the preview
Go deeper on NCT05417282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417282.